🚨 Everything is back in stock — all peptides available now 🚨

Peptide blends: GLOW, KLOW, Wolverine and CJC-IPA

PRECLINICAL ONLY

No blend has been tested in any trial. Evidence exists only for individual components.

At a glance. Four co-lyophilized combinations, each containing compounds that have been studied separately but never together.

Written and maintained by the AVERON Research Desk · Last reviewed September 2026

What these blends are

Each blend below combines two or more compounds in fixed proportions in a single vial. They are co-lyophilized: mixed as a liquid at the factory and freeze-dried together into one uniform powder. AVERON does not mix compounds itself. How blends work in general is explained in peptide blends explained.

The most important thing to know about all four: no trial has ever tested any of these combinations. The evidence for each blend is only the evidence for its individual components, and for most of those components the evidence is animal research.

GLOW — 70 mg

ComponentAmount
GHK-Cu50 mg
BPC-15710 mg
TB-50010 mg

Combines a copper peptide studied topically for skin with the two most widely used repair peptides. GLOW is associated with both skin quality and tissue recovery. The solution is blue because of the copper in GHK-Cu.

Component evidence: GHK-Cu — early human data, topical only · BPC-157 — preclinical only · TB-500 — preclinical only.

KLOW — 80 mg

ComponentAmount
GHK-Cu50 mg
BPC-15710 mg
TB-50010 mg
KPV10 mg

The GLOW combination with KPV added, a small peptide studied in mice for its anti-inflammatory activity in the gut.

Component evidence: as for GLOW, plus KPV — preclinical only.

Wolverine — 20 mg

ComponentAmount
BPC-15710 mg
TB-50010 mg

The two repair peptides together in equal amounts, in one vial instead of two.

Component evidence: BPC-157 — preclinical only · TB-500 — preclinical only.

CJC-IPA — 10 mg

ComponentAmount
CJC-1295 without DAC5 mg
Ipamorelin5 mg

Two compounds that stimulate growth hormone release through different pathways.

Component evidence: CJC-1295 and Ipamorelin — early human data for each compound separately, none for the combination.

How blends are tested

For a blend, independent laboratories report the identity and amount of each component, but not a purity figure. The impurities of several peptides overlap in the analysis and cannot be separated. That is a limit of the method, not a sign of a poor product. See HPLC purity explained.

What it does not do, and what is not known

  • None of these combinations has been tested in a human or animal trial as a combination.
  • Combining compounds does not add up their evidence. A blend of three preclinical compounds is still preclinical.
  • The proportions are fixed. More of one component always means proportionally more of the others.
  • Whether the compounds interact with each other in the body is unknown.
  • GLOW and KLOW contain copper, which can react with other compounds, so they should never share a vial or cartridge with anything else.

Adverse effects reported in research

There is no safety data for any of these combinations. The individual component pages describe what is and is not known for each.

Anti-doping status

GLOW, KLOW and Wolverine all contain BPC-157, named on WADA's Prohibited List under S0, and TB-500, named under S2.

CJC-IPA contains CJC-1295 and ipamorelin, both named under S2.

All four blends are prohibited at all times in tested sport.

At AVERON

BlendStatusIndependent lab report
GLOW 70 mgIn stock93199_R74PCJVXZPNI
CJC-IPA 10 mgIn stock105140_N2WTIRKQ1D9A
KLOW 80 mgArrivingPublished before sale
Wolverine 20 mgArrivingPublished before sale

Frequently asked questions

GHK-Cu 50 mg, BPC-157 10 mg and TB-500 10 mg, co-lyophilized in one 70 mg vial.

KLOW contains everything in GLOW plus 10 mg of KPV.

BPC-157 10 mg and TB-500 10 mg in one 20 mg vial.

No. None of these combinations has been tested. The evidence is only for individual components.

Yes. All four contain at least one compound named on WADA's Prohibited List.

Because the impurities of several peptides overlap in the analysis. Laboratories report identity and amount for each component instead.

Doses mentioned on this page are the arms of published studies, given to describe their results. They are not guidance.

Sources

  1. Janoshik Analytical. Public test verification portal. Janoshik Analytical. Link
  2. World Anti-Doping Agency. The Prohibited List. WADA. Link

Related pages

...